Jonathan W. Simons | |
---|---|
Born | Washington, D.C., U.S. |
Alma mater | Princeton University Johns Hopkins School of Medicine |
Scientific career | |
Institutions | |
Medical career | |
Profession | Physician-scientist |
Sub-specialties | Oncologist |
Research | Prostate cancer |
Jonathan W. Simons is an American physician-scientist, [1] medical oncologist, and leader in prostate cancer research. [2] In August 2021, Simons was appointed the medical director and Chief Science Officer of the Marcus Foundation. [3] Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. [4] Simons’ laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis [5] [6] and principles of “broken immune tolerance” via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons’ clinical team took the biotechnology into the world’s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins. [7]
Simons was raised in Ithaca, New York. He is the husband, son, and grandson of cancer survivors. Simons’ father, David M. Simons, a professor at Cornell University, was among the first thousand patients cured of relapsed Hodgkin’s Lymphoma as a part of participation in National Cancer Institute clinical trials. Simons is the grandson of M.L. Wilson, who served as the Under Secretary of Agriculture under President Franklin Roosevelt. A 1976 graduate of Ithaca High School, Simons graduated magna cum laude from Princeton University with an A.B. in biochemistry in 1980. [8] Before entering medical school, Simons had a concentration in the Shakespeare Canon as a Rotary International Postgraduate Fellow in the Humanities at the University of Kent in Canterbury, England; subsequently he had a Nuffield Foundation research scholarship in the Department of Biochemistry at the University of Cambridge in 1981. [8]
Simons received an MD degree from the Johns Hopkins University School of Medicine in 1985. He completed his residency in internal medicine at Massachusetts General Hospital and a clinical fellowship in medical oncology at the Johns Hopkins Oncology Center. [8]
Simons is board-certified in internal medicine and medical oncology. At Johns Hopkins, Simons completed a post-doctoral fellowship under Bert Vogelstein in human cancer molecular genetics prior to being appointed to the Hopkins medical school faculty in oncology and urology in 1991. [8] On the Hopkins faculty, Simons chaired the Hopkins medical school Curriculum Committee for Oncology from 1990 to 2000. Simons' first independent laboratory research grant was from the Prostate Cancer Foundation (formerly known as CaPCure) in the Foundation’s first year of existence in 1993.
Simons was recruited by Georgia Governor Roy Barnes, and the Robert W. Woodruff Foundation of Atlanta to be the Founding Director of the Winship Cancer Institute at Emory University and Chair of Hematology and Oncology at the Emory Clinic. [9] [8] Simons led the creation of the Georgia State Cancer Plan, Georgia’s tobacco settlement investment in cancer research and new faculty recruitment programs within the Georgia Cancer Coalition. [10] Simons co-directed with Shuming Nie the National Cancer Institute Center for Cancer Nanotechnology Excellence at Emory and Georgia Institute of Technology. [11] From 2000 to 2006, Simons was a Distinguished Service Professor of Hematology and Oncology at the Emory University School of Medicine, and Professor of Materials Sciences Engineering at the Georgia Institute of Technology.
With Michael Milken, chairman of the board of FasterCures, Simons created the strategic plan and served as the interim chief science officer for the launch of the Melanoma Research Alliance. The Melanoma Research Alliance was founded by Debra and Leon Black in 2007. [12]
In 2011, Simons was inducted into the Johns Hopkins University Society of Scholars. The society inducts former postdoctoral fellows, postdoctoral degree recipients, house staff and junior or visiting faculty who have served at least a year at Johns Hopkins and thereafter gained marked distinction elsewhere in their fields. [13]
Simons received the Johns Hopkins University Distinguished Alumni Award in 2020 from the Johns Hopkins University School of Medicine. [14]
Simons has led the expansion of PCF’s Research Awards globally to over 800 research awards in 22 countries including $590.0 million invested in peer-reviewed funding to 240 teams of scientists working on human genetics, molecular oncology, genomic medicines, molecular imaging, and "precision immunotherapy". [15] In total, funding from the PCF Research Enterprise has propelled 14 FDA approvals in prostate cancer. [15]
In 2008, 2011, and 2012, Simons launched new peer-reviewed research programs in the United Kingdom, China, and Ireland. The Prostate Cancer Foundation also increased its support for cancer researchers in Australia, Canada, and Greece through the PCF Hellenic Fund. In 2020, the PCF Global Research Enterprise extended to award investigators in 22 countries. [15]
When Simons joined the Prostate Cancer Foundation in 2007, he launched the “PCF 100”, with the goal of securing support for 100 Young Investigators. Each Young Investigator receives a three-year award and total grant amount of $225,000, which is matched dollar-for-dollar by his or her university. PCF has invested more than $70 million to support 314 young investigators since 2007. [16]
In 2016, as a part of Vice President Biden's Cancer Moonshot initiative, Simons announced a 5-year, Foundation-Government partnership with the Department of Veterans Affairs for a precision oncology clinical research and care program for every US veteran with prostate cancer in the VA. [17] [18]
In 2020, Simons launched the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne, Australia. [19]
The Johns Hopkins University School of Medicine (JHUSOM) is the medical school of Johns Hopkins University, a private research university in Baltimore, Maryland. Founded in 1893, the School of Medicine shares a campus with Johns Hopkins Hospital and Johns Hopkins Children's Center, established in 1889.
Daniel F. Roses is an American surgeon who is the Jules Leonard Whitehill Professor of Surgery and Oncology of the New York University School of Medicine and a Senior Attending Surgeon at Tisch Hospital of the New York University Medical Center.
David B. Agus is an American physician, cancer researcher and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. He is also the author of four books.
James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.
John E. Niederhuber was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.
Winship Cancer Institute of Emory University is a nonprofit cancer research and patient care center based in Atlanta, Georgia. Winship Cancer Institute is the only National Cancer Institute-designated Comprehensive Cancer Center in Georgia.
Walter "Wally" J. Curran, Jr. is an American radiation oncologist specializing in the treatment of malignant brain tumors and locally advanced lung cancer.
J. William Harbour is an American ophthalmologist, ocular oncologist and cancer researcher. He is Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the vice chair and director of ocular oncology at the Bascom Palmer Eye Institute and associate director for basic science at the Sylvester Comprehensive Cancer Center of the University of Miami's Miller School of Medicine.
Gregg Leonard Semenza is an American pediatrician and Professor of Genetic Medicine at the Johns Hopkins School of Medicine. He serves as the director of the vascular program at the Institute for Cell Engineering. He is a 2016 recipient of the Albert Lasker Award for Basic Medical Research. He is known for his discovery of HIF-1, which allows cancer cells to adapt to oxygen-poor environments. He shared the 2019 Nobel Prize in Physiology or Medicine for "discoveries of how cells sense and adapt to oxygen availability" with William Kaelin Jr. and Peter J. Ratcliffe. Semenza has had thirteen research papers retracted due to falsified data.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is an NCI-Designated Comprehensive Cancer Center in Baltimore, MD. It was established in 1973 and received its NCI designation that same year as one of the first designated cancer centers in the country.
Scott M. Lippman is the former Director of Moores Cancer Center at the University of California, San Diego and current Professor of Medicine at UC San Diego School of Medicine.
Ashani Tanuja Weeraratna is a Sri Lanka-born American cancer researcher whose findings are contributing to the scientific understanding of melanoma tumors. She is a Bloomberg Distinguished Professor of cancer biology and the E.V. McCollum Professor and Chair of the department of biochemistry and molecular biology at the Johns Hopkins Bloomberg School of Public Health. Weeraratna is a member of the National Cancer Advisory Board, which advises and assists the director of the National Cancer Institute on the activities of the national cancer program.
Padmanee Sharma is an immunologist and oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. She holds the position of professor of genitourinary medical oncology and immunology in the Division of Cancer Medicine where she specializes in renal, prostate, and bladder cancers.
Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.
Taofeek Kunle Owonikoko is an American physician who is Professor and Vice-Chair for Faculty Development, Department of Haematology and Medical Oncology at the Winship Cancer Institute. His research considers small cell lung cancer. He was a 2019 Emory University Woodruff Leadership Academy Fellow.
Soma Sengupta is a British-American physician-scientist. She is a specialty board certified neuro-oncologist board certified Neurologist and fellowship-trained in Integrative Medicine. Her clinical interests span treatment of brain tumor patients, integrative approaches in neurology and oncology, as well as healthcare policy. She is a full-time faculty member in the Departments of Neurology and Neurosurgery at the University of North Carolina at Chapel Hill, where she is a Full Professor, Vice Chair, member of the Lineberger Comprehensive Cancer Center, and Chief of the Division of Neuro-Oncology. She is also a Bye Fellow at Lucy Cavendish College, University of Cambridge, U.K.
Theodore L. DeWeese, M.D., is the Francis Watt Baker, M.D. and Lennox D. Baker, M.D. dean of the medical faculty at Johns Hopkins University School of Medicine and the chief executive officer of Johns Hopkins Medicine. He was appointed in December 2023 after serving in an interim capacity for 18 months.